An Open-label, Cross-over, Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects.

Trial Profile

An Open-label, Cross-over, Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2012

At a glance

  • Drugs E 3710; Esomeprazole; Rabeprazole
  • Indications Bleeding ulcer; Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; NSAID-induced ulcer; Peptic ulcer; Reflux oesophagitis; Zollinger-Ellison syndrome
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 19 May 2012 Primary endpoint 'Intragastric-pH' has been met.
    • 19 May 2012 Results presented at the Digestive Disease Week 2012.
    • 13 Mar 2012 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top